Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: A case report

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Gani, Linsey U ^a   Gianatti, Emily J ^a   Cheung, Ada S ^a   Jerums, George ^a   MacIsaac, Richard J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANYL 1 TYROSYL 3 OCTREOTIDE GA 68; CHROMOGRANIN; CORTICOTROPIN; FLUORODEOXYGLUCOSE F 18; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; RADIOPHARMACEUTICAL AGENT; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ACNE; ADRENALECTOMY; ADULT; ALOPECIA; AMENORRHEA; ANXIETY; ARTICLE; BRONCHUS CARCINOID; CANCER SURGERY; CASE REPORT; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC IMAGING; ECTOPIC CORTICOTROPIN PRODUCTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIRSUTISM; HUMAN; HUMAN RELATION; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS; IMMOBILIZATION; LETHARGY; MUSCLE WEAKNESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORACOTOMY; THORAX RADIOGRAPHY; TREATMENT FAILURE; TUMOR DIAGNOSIS; WEIGHT GAIN;

EID: 80052029966     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-405     Document Type: Article

References (8)

1. Lack of utility of 111In-Pentreotide Scintigraphy in Localizing Ectopic ACTH Producing Tumors: Follow-Up of 18 Patients. Torpy DJ, Chen CC, Mullen N, Doppmann JL, Carrasquillo JA, Chrousos GP, Nieman LK, J Clin Endocrinol Metab 1999 84 1186 1192 10.1210/jc.84.4.1186 10199751 (Pubitemid 30644373)
2. Clinical indications for gallium-68 positron emission tomography imaging. Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A, Euro J Surg Onc 2009 35 561 567
3. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. Aron DC, Raff H, Findling JL, J Clin Endocrinol Metab 1997 82 1780 1785 10.1210/jc.82.6.1780 9177382 (Pubitemid 127495186)
4. Successful application of technetium-99 m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropin-producing bronchial carcinoid lung tumor: a case report. Esfehani AF, Chavoshi M, Noorani MH, Saghari M, Eftekhari M, Beiki D, Fallahi B, Assadi M, J Med Case Reports 2010 4 323 10.1186/1752-1947-4-323 20955547
5. Continuous dexamethasone infusion for seven hours in patients with the Cushing syndrome. A superior differential diagnostic test. Biemond P, de Jong FH, Lamberts SW, Ann Intern Med 1990 112 738 742 2158760 (Pubitemid 20170212)
6. The corticotropin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's Syndrome. Reimondo G, Paccotti P, Minetto M, Termine A, Stura G, Bergui M, Angeli A, Terzolo M, Clin Endo 2003 58 718 724 10.1046/j.1365-2265.2003.01776.x (Pubitemid 36702731)
7. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman AB, Besser GM, J Clin Endocrinol Metab 2006 91 371 377 16303835 (Pubitemid 43236895)
8. The role of [18F] fluorodeoxyglucose positron emission tomography and [111 In]-diethylenetriaminepentaacetate-D-Phe-pentreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK, J Clin Endocrinol Metab 2004 89 2214 2221 10.1210/jc.2003-031812 15126544 (Pubitemid 38619855)